Dr. Lu is Associate Professor in the Department of Electrical Engineering and Computer Science and in the Department of Biological Engineering at MIT and is an Associate Member of the Broad Institute. He received undergraduate and master of engineering degrees from MIT, an M.D. from Harvard Medical School, and a Ph.D. from the Harvard-MIT Health Sciences and Technology Medical Engineering and Medical Physics Program. He has won the NIH New Innovator Award, the NSF CAREER Award, the Presidential Early Career Award for Scientists and Engineers (PECASE), Young Investigator Prizes from the Army and Navy, the Lemelson-MIT Student Prize, and Grand Prize in the National Inventor Hall of Fame’s Collegiate Inventors Competition. He was named to the 2010 TR35 for “Top Young Innovators Under 35” by Technology Review. Dr. Lu is a frequent speaker on phage technology at prominent scientific conferences and has authored multiple phage-related articles published in peer-reviewed journals.
Robert T. Schooley, MD, is an infectious disease physician at the University of California, San Diego (UCSD), UCSD’s Senior Director of International Initiatives, and Vice Chair of Academic Affairs in the Department of Medicine. Dr. Schooley is the Editor-in-Chief of Clinical Infectious Diseases journal and formerly served as Chief of Division of Infectious Diseases at UCSD. Dr. Schooley began his research career studying the immunopathogenesis of herpesvirus infections in immunocompromised patients but shifted his focus to AIDS in 1981 when the first cases of this syndrome began to appear in Boston. His research group was among the first to delineate the humoral and cellular immune responses to HIV infection. Over the next 15 years he became increasingly involved in the discovery and development of antiretroviral chemotherapeutic agents including reverse transcriptase inhibitors, protease inhibitors and entry inhibitors. He has over 30 years of experience in development of anti-infective therapies and has led treatment of critically ill patients using bacteriophage therapeutics under FDA-allowed Emergency INDs.
Dr. Schooley received his medical degree from the Johns Hopkins University School of Medicine in 1974 and completed his medical house staff training at the Johns Hopkins Hospital in 1976. He completed fellowships in infectious diseases at the National Institute of Allergy and Infectious Diseases and at the Massachusetts General Hospital before joining the faculty of Harvard Medical School in 1981.